Skip to main content

Vaccinia Capping System (C09-1082-500)

Aladdin

Catalog No.
C09-1082-500
Manufacturer No.
V406621-500U
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $3,397.13
List Price: $3,774.59

Product DescriptionThe vaccinia virus capping system uses the vaccinia virus capping enzyme and related components to add the 7-methylguanosine cap structure (m7Gppp, Cap0) to the 5´ end of the RNA. In eukaryotes, this structure is closely related

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
Product DescriptionThe vaccinia virus capping system uses the vaccinia virus capping enzyme and related components to add the 7-methylguanosine cap structure (m7Gppp, Cap0) to the 5´ end of the RNA. In eukaryotes, this structure is closely related to the stability, transport and translation of mRNA. Using an enzymatic reaction to cap RNA is a simple and effective method, and the cap structure is exactly the same as the natural Cap 0 structure, which can significantly improve the stability and translation ability of RNA used for in vitro transcription, transfection, and microinjection. This enzyme is composed of two subunits (D1 and D12). The D1 subunit performs the functions of RNA triphosphatase and guanosine transferase, and the D12 subunit performs the function of guanine methyltransferase. They are essential for adding a complete The Cap 0 structure m7Gppp5´N is required.Figure 1. The structure and mechanism of vaccinia virus capping. a. Co-crystal structure of vaccinia virus capping enzyme, GTP (red) and SAH (rose red) (PDB 4CKB). The enzyme is composed of two subunits, D1 and D12, and has the functions of RNA triphosphatase (blue), guanosine transferase (orange) and guanine methyltransferase (beige). This figure is quoted from Ramanathan, A., Robb, GB, & Chan, SH (2016). mRNA capping: biological functions and applications. Nucleic Acids Res 44(16), 7511–7526. b. The cap structure of mRNA consists of a 7-Methylguanosine is composed of a 5'-5' triphosphate bridge connected to the 5'nucleoside of the mRNA chain. The Cap-0 structure is formed by the sequential reaction of three adjacent RNA strands. The further formation of cap-1 structure requires the participation of 2'-O-methyltransferase, which can reduce the cellular innate immune response caused by RNA in vivo. This figure is quoted from Decroly, E., Ferron, F., Lescar, J. et al. (2012). Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Microbiol 10, 51–65.This system can be used for the capping reaction of IVT RNA, so that the capping reaction is completed within 1 hour, the efficiency is close to 100%, and the correct direction is guaranteed.Product UsageIn vivo or in vitro pre-translational capping of mRNA and 5'end labeling of mRNA.PrecautionsSAM: It is necessary to calculate the amount of SAM in advance, and dilute the aliquoted 32 mM stock solution to 2 mM working solution before the reaction starts. SAM is unstable at pH 7-8 and 37°C and needs to be freshly prepared before the reaction starts. To avoid degradation of SAM, this working solution needs to be stored on ice.RNA: Before using the capping system, the RNA produced by the in vitro transcription reaction should be purified and dissolved in RNase-free water. The RNA should not be dissolved in EDTA solution or other salt solutions.RNA secondary structure: Some RNA transcripts may form stable secondary structures (homodimers and hairpin structures). For example, the secondary structure occurring at the 5'end of the transcript will affect the capping efficiency. Heating RNA before reacting with the capping enzyme can remove the secondary structure at the 5´ end of the transcription product. If the 5´ end of the transcription product has a complex structure, the heating time can be extended to 10 minutes, and the capping reaction time can be extended to 60 minutes.Cap 0- and Cap 1-mRNA: The difference between Cap 0- and Cap 1-mRNA is whether the first nucleotide (N1) next to the cap structure at the 5'end of RNA has a 2'-O-methyl group. In higher eukaryotic cells, this methylation is part of the natural capping process, and the Cap 1 structure improves the translation efficiency of mRNA.Poly(A) tail: If the capped RNA needs to be added with 3'-poly(A) tail, E. coli Poly(A) Polymerase can be used for tailing. The capped and tailed RNA needs to be purified before the RNA transfection experiment.RNase Inhibitor: When configuring the reaction system, you can add 0.5 µl of RNase inhibitor and remove an equal volume of RNase-free water.RNA 5'end labeling: When used for RNA 5'end labeling, the GTP stock solution should be diluted to 1-3 times the mRNA concentration.
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
0.96 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
V406621-500U
Product Size:
500U


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.